Sun, Dec 28, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Valeant Welcomes John Paulson’s $1bn stake in Allergan

Wednesday, July 02, 2014

Komfie Manalo, Opalesque Asia:

Valeant Pharmaceuticals Inc's chief executive Michael Pearson on Thursday welcomed news that hedge fund manager John Paulson through his firm, Paulson & Co., is building a $1bn stake in Allergan, Reuters said.

Deal-making drug-maker Valeant has partnered with activist hedge fund manager Bill Ackman of Pershing Square to acquire Allergan and shake up its board.

In an interview with Canada's BNN TV, Pearson said he was delighted with Paulson’s move to buy six million shares at Allergan. "We do believe we'll get the 25 percent and the majority we need to get this deal consummated," he was quoted as saying.

According to the report, Paulson’s position, together with Pershing Square’s stocks, are sufficient to provide the group with a 25% support of Allergan shares required to call the special meeting to replace majority of Allergan’s current sitting board.

On Wednesday, Paulson announced he has built a $1bn stake in Allergan and supports a takeover of the Botox maker by Valeant. Paulson's position is a boost to Valeant and its partner in the hostile bid, Ackman. Valean......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its